Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user has experienced hair regrowth using finasteride, minoxidil, dermarolling, and nizoral shampoo, but is considering a hair transplant due to advanced hair loss. Others suggest checking the donor area and considering a reputable surgeon for a potential transplant.

A user shared progress pictures showing improvement from NW6 diffuse to NW1 after 5 months of finasteride and 2 months of dutasteride. Another user asked if these treatments affected beard or body hair thickness.

The user experienced significant hair regrowth and minimal side effects after six months of using finasteride. They recommend trying finasteride but advise stopping if side effects occur.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user experienced hair regrowth after six months using 0.5 mg dutasteride and 5 mg oral minoxidil with 6% topical minoxidil. Some users suggested adding microneedling for further improvement.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.

Hair loss may be influenced by mechanical tension and inflammation, with the hi-c5 protein amplifying androgen effects, leading to follicle miniaturization. Treatments like finasteride, minoxidil, and scalp massages are suggested to manage hair loss.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

A user shared their 6-month progress using 1mg finasteride, daily minoxidil, 1.5mm microneedling twice a week, biotin, and Nizoral shampoo, showing significant hair regrowth. Other users were impressed, noting the regrowth resembled a hair transplant.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The user shared their 6-month hair regrowth progress using finasteride, minoxidil, biotin, and iron supplements, along with occasional microneedling and specific shampoos. They reported minimal side effects and no retrograde alopecia, attributing their success to a combination of treatments.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

The user experienced aggressive hair loss despite using oral finasteride and minoxidil, with additional issues like dandruff and eyebrow hair loss. They are considering switching to oral minoxidil and dutasteride due to scalp inflammation and lack of improvement.

Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.

Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for treating alopecia and wound healing. They enhance cell viability, maintain stemness, and promote hair and tissue regeneration without teratoma formation.

The conversation discusses a user's six-month progress in treating hereditary hair loss using a regimen that includes minoxidil, finasteride, dutasteride, and other medications. Opinions vary on the effectiveness and logic of the treatment, with some users suggesting additional methods like microneedling.

The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.

Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.

The user improved their hair loss from a Norwood scale 2.5/3 to 1.5/2 using treatments including 2.5 mg dutasteride, RU58841, 15 mg oral minoxidil, isoflavones, NAC, pumpkin seed oil, NAD+, and Vipelin, but still experiences temple recession. Other users expressed concern over the high dosages of oral minoxidil and dutasteride.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.

Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for alopecia treatment. They enhance cell viability, maintain stemness, and induce hair growth without teratoma formation.

The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.

The conversation discusses the effectiveness of Vichy Dercos Aminexil Clinical R.E.G.E.N. Booster for hair shedding and thinning. The main ingredient, Aminexil, is compared to Minoxidil, and the user seeks real experiences to determine its efficacy.

KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.

The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.

The user has been using a topical combination of finasteride and minoxidil for six months, with some progress noted. They also use Nizoral twice a week and plan to start microneedling.

A 23-year-old male has been using oral finasteride and topical minoxidil for 6.5 months but is concerned about continued hairline recession and thinning. He is considering switching to dutasteride, while others suggest being patient, trying oral minoxidil, or using topical finasteride.